Boehringer Ingelheim today announces the start of the THULITE Phase II clinical study (NCT06962839). It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral ...

A proposed layout for the initial phase of Rochester’s planned sports and recreation complex has been finalized.